Germany Performs First Regular CRISPR Gene-Editing Treatment at Charité Berlin
- A 19-year-old patient diagnosed with severe beta-thalassemia has become the first person in Germany to receive a commercially approved gene-editing therapy using CRISPR technology.
- Beta-thalassemia is a serious, genetically inherited blood disorder caused by mutations in the gene responsible for producing hemoglobin, the iron-containing protein in red blood cells that carries oxygen...
- Because Mohammad was too old for a conventional donor transplant, physicians at the Berliner Charité administered the gene therapy drug Casgevy, also known by the active ingredient Exagamglogene...
A 19-year-old patient diagnosed with severe beta-thalassemia has become the first person in Germany to receive a commercially approved gene-editing therapy using CRISPR technology. Treated at the Berliner Charité, the patient, named Mohammad, no longer requires regular blood transfusions following the intervention. The therapy utilizes the medicine Casgevy, which modifies a patient’s own bone marrow stem cells outside the body to restore normal hemoglobin production.
Severe Beta-Thalassämie and the Limits of Traditional Transplants
Beta-thalassemia is a serious, genetically inherited blood disorder caused by mutations in the gene responsible for producing hemoglobin, the iron-containing protein in red blood cells that carries oxygen throughout the body. Severe forms of the illness cause profound fatigue, pain, and developmental impairments, alongside dangerous iron accumulations that damage internal organs. According to figures provided by the Charité, approximately 60,000 children are born with severe beta-thalassemia worldwide every year. To stay alive, affected children typically require blood transfusions every three weeks, a routine that carries cumulative, severe side effects. While traditional donor stem cell transplants can cure the condition, patients generally must be no older than roughly 14 years old to undergo the procedure, leaving older teenagers without standard curative options.
Physicians Use CRISPR to Modify Mohammad's Stem Cells
Because Mohammad was too old for a conventional donor transplant, physicians at the Berliner Charité administered the gene therapy drug Casgevy, also known by the active ingredient Exagamglogene Autotemcel. The treatment involves extracting bone marrow stem cells from the patient, altering them in a laboratory using the Nobel Prize-winning CRISPR gene-editing method, and returning them via an intravenous infusion. In May 2026, medical staff returned 900 million genetically modified stem cells to the 19-year-old patient. Lena Oevermann, head of the hemoglobinopathy program at the Charité, explained that it takes about six months for the modified cells to achieve full hemoglobin production. During a hospital visit following the procedure, CRISPR co-developer and Nobel laureate Emmanuelle Charpentier personally visited the patient.
Chemotherapy Creates Risks of Infertility and Liver Damage
The therapeutic process carries substantial risks and rigorous physical demands. Before receiving the modified cells back into the body, patients must undergo a conditioning chemotherapy regimen to clear space in the bone marrow. Oevermann noted that this chemotherapy can cause painful mucosal inflammation and liver damage, and it carries a high likelihood of causing infertility. Medical teams currently lack long-term safety and efficacy data regarding the novel gene therapy. Because of these unknowns, the European Union’s 2024 drug approval for Casgevy requires strict conditions, including a mandatory 15-year patient follow-up observation period. In Germany, health insurance funds cover the high costs of the treatment, provided the treating clinic submits a specialized application.
Resource Constraints Limit Annual Patient Capacity
Medical experts emphasize that logistical hurdles will restrict how widely the therapy can be deployed. Joachim Kunz of the Heidelberg University Hospital previously pointed out that the procedure is exceptionally complex and demands extensive resources, meaning it will not be universally scalable in the near future and will remain restricted to a limited number of patients each year. Despite these resource limitations, the Berliner Charité confirmed that Mohammad’s immune system has successfully regenerated and his overall health status is excellent.